干扰素与拉米夫定序贯治疗慢性乙型肝炎疗效观察

Therapeutic Efficacy of Sequential Therapy of Interferon and Lamivudine in Chronic Hepatitis B

目的:研究干扰素(IFN-α2b)与拉米夫定序贯治疗慢性乙型肝炎(CHB)的临床疗效。方法:将90例患者随机分为治疗组和对照组,对照组45例,单用干扰素治疗,治疗组45例,序贯应用拉米夫定及干扰素治疗,疗程均为8个月,检测治疗前后及停药6个月后患者的肝功能指标及病毒学指标。结果:治疗结束及停药6个月后,治疗组血清谷丙氨酸转移酶(ALT)水平均较治疗前明显下降(P<0.05),治疗组HBeAg阴转率,HBeAg/抗-HBe血清转换率,HBV-DNA阴转率均显著高于对照组(P<0.05),治疗过程中两组没有出现严重不良反应,两组不良反应无明显差异。结论:干扰素(IFN-α2b)与拉米夫定序贯疗法抗HBV及改善肝功能临床效果明显,不良反应轻。

Objective：Interferon（IFN-α2b） consistent with the treatment of chronic hepatitis B（CHB） with lamivudine of clinical efficacy.Methods：90 patients were randomly divided into treatment group and control group,control group 45 cases,interferon therapy,the treatment group 45 patients,sequential therapy of lamivudine and interferon,Course of treatment was 8 months,Observed the changes of liver function and Virological indicators,Before and after treatment and 6 months after drug withdrawal in patients.Results：End of treatment and 6 months after stopping treatment serum alanine aminotransferase Valley（ALT） levels decreased significantly compared with before treatment（P 0.05） the negative conversion rate of HBeAg and HBeAg /anti-HBe serum conversion rate,HBV-DNA of the treatment group were significantly higher,the two groups during the treatment without serious adverse reactions,side effects were no significant differences in the two groups.Conclusion：Interferon（IFN-α2b） and sequential therapy of lamivudine resistant HBV and significantly improve the clinical results of liver function,adverse reactions.